Skip to end of metadata
Go to start of metadata

The MTL welcomes opportunities to assist in the development or application of other pertinent discovery tools, which might include more specialized bioassays, screens, reagents or related technology of interest to CCR investigators. The MTL is eager to collaborate in the evaluation or implementation of a broad range of available or evolving "discovery" and validation technologies, including proprietary methods, hardware, software, compounds or collections, from the private-sector. In so doing, the MTL intends to enhance the CCR's intramural capabilities for follow-up investigations of screening hits, bioprobe or drug-lead discovery and characterization, identification and validation of new molecular targets, and other pertinent research supporting preclinical or clinical advancement of molecular therapeutics, diagnostics and imaging.

© 2000-2016 Center for Cancer Research at the National Cancer Institute.
questions, comments, and suggestions to webmaster

Last updated by Beutler, John (NIH/NCI) [E] on Oct 21, 2016